305448-20-8

Basic information

• Product Name: 1-AMINO-2-(4-BENZYLOXY-PHENYL)-PROPAN-2-OL
• Synonyms: 1-AMINO-2-(4-BENZYLOXY-PHENYL)-PROPAN-2-OL
• CAS NO: 305448-20-8
• Molecular Formula: C₁₆H₁₉NO₂
• Molecular Weight: 257.33
• Product Categories: pharmacetical
• Mol File: 305448-20-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-AMINO-2-(4-BENZYLOXY-PHENYL)-PROPAN-2-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-AMINO-2-(4-BENZYLOXY-PHENYL)-PROPAN-2-OL(305448-20-8)
• EPA Substance Registry System: 1-AMINO-2-(4-BENZYLOXY-PHENYL)-PROPAN-2-OL(305448-20-8)

Safety Data

• Hazardous Substances Data: 305448-20-8(Hazardous Substances Data)

Usage

General Description

1-AMINO-2-(4-BENZYLOXY-PHENYL)-PROPAN-2-OL, also known as 4-benzyloxyphenylisopropanolamine, is an organic compound that consists of a benzyl group bonded to an oxygen atom, and an amino group attached to the second carbon of a propan-2-ol molecule. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and fine chemicals. It has potential therapeutic applications due to its ability to interact with biological receptors and enzymes, making it a valuable precursor for drug development. Additionally, its structure and properties make it useful in the creation of novel drugs with specific biological activities. Overall, 1-AMINO-2-(4-BENZYLOXY-PHENYL)-PROPAN-2-OL is an important building block in organic chemistry with potential applications in the pharmaceutical industry.

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 54696-05-8 4'-benzyloxy-acetophenone 
• 124499-17-8 1-amino-2-[4-(phenylmethoxy)phenyl]propan-2-ol hydrochloride 

Downstream Products

• 1268861-74-0 1-benzylamino-2-(4-benzyloxy-phenyl)-propan-2-ol 
• 305448-24-2 {2-hydroxy-2-[4-(phenylmethoxy)phenyl]propyl}[(methylethyl)sulfonyl]amine 

Relevant articles and documents

(THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS

The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

Method of treating stroke

The present invention provides a method of treating stroke in a patient comprising administering to said patient an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.